AI Article Synopsis
- * There have been instances of lupus erythematosus developing after IL-17 inhibition, but this report highlights a unique case where a 57-year-old man developed membranous lupus nephritis after receiving secukinumab.
- * Following the development of lupus nephritis, the patient was treated with various medications, including tacrolimus and belimumab, showing improvement; however, further investigation is necessary to understand the link between IL-17 inhibition and lupus.
Article Abstract
The interleukin (IL)-17 axis is involved in many inflammatory and autoimmune diseases. Secukinumab, an IL-17 inhibitor, has been approved for psoriasis treatment. There are accumulating cases of lupus erythematosus induced by IL-17 inhibition. Lupus nephritis after IL-17 inhibition has not been reported. We report the case of a 57-year-old man who developed membranous lupus nephritis after secukinumab treatment for psoriasis. Anti-SSA and PM-Scl antibodies were positive. dsDNA, anti-Smith, and anti-histone antibodies were negative, and serum complement was low. Secukinumab was discontinued, while tacrolimus was initiated, subsequently switched to cyclosporin, belimumab, glucocorticosteroid, and hydroxychloroquine with a good response. The relationship between lupus erythematosus and IL-17 inhibition requires further research.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/09612033241242698 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!